  | Lombardo, G., HAFRAOUI, K., Beguin, Y., & VERTENOEIL, G. (February 2024). Comment j’explore … une polyglobulie. Revue Médicale de Liège, 79 (2), 110 - 115.  Editorial Reviewed verified by ORBi |
 | WITHOFS, N., Beguin, Y., COUSIN, F., Tancredi, T., SIMONI, P., Alvarez-Miezentseva, V., DE PRIJCK, B., HAFRAOUI, K., Bonnet, C., Baron, F., Hustinx, R., & Caers, J. (2019). Dual-tracer PET/CT scan after injection of combined [ 18 F]NaF and [ 18 F]FDG outperforms MRI in the detection of myeloma lesions. Hematological Oncology, 37, 193-201. doi:10.1002/hon.2600 Peer Reviewed verified by ORBi |
 | Huart, J., Visée, C., Colassin, A., Marechal, P., HAFRAOUI, K., & Davin, L. (July 2018). Syndrome coronarien aigu lié à une maladie de Vaquez. Revue Médicale de Liège, 73 (7-8), 397 - 401. Editorial Reviewed verified by ORBi |
SID, S., Baron, F., WILLEMS, E., Caers, J., Bonnet, C., DE PRIJCK, B., LEJEUNE, M., HAFRAOUI, K., Servais, S., JASPERS, A., & Beguin, Y. (November 2016). Hematologic recovery after autologus stem cell transplantation in multiple myeloma: a single center experience of 225 patients [Paper presentation]. 16ème Congrès commun de la SFGM-TC & 8ème de la SFBCT, Liège, Belgium. |
  | WITHOFS, N., COUSIN, F., TANCREDI, T., SIMONI, P., DE PRIJCK, B., HAFRAOUI, K., BONNET, C., HUSTINX, R., BEGUIN, Y., & CAERS, J. (14 June 2016). Comparison of combined whole-body 18F-NAF and 18F-FDG PET/CT versus MRI for the detection of myeloma lesions [Paper presentation]. SNMMI 2016 Annual Meeting. |
 | Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872 Peer Reviewed verified by ORBi |
 | JASPERS, A., Baron, F., SERVAIS, S., LEJEUNE, M., WILLEMS, E., SEIDEL, L., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (September 2015). Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. American Journal of Hematology, 90 (9), 197-199. doi:10.1002/ajh.24100 Peer Reviewed verified by ORBi |
 | JASPERS, A., Baron, F., Maertens, J., DE PRIJCK, B., Schots, R., Bonnet, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & Beguin, Y. (July 2015). Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation [letter to the editor]. American Journal of Hematology, 90 (7), 133-4. doi:10.1002/ajh.24013 Peer Reviewed verified by ORBi |
 | JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948. Peer Reviewed verified by ORBi |
 | CAERS, J., HAFRAOUI, K., KEUTGENS, A., CABERG, J.-H., LAMBERT, F., TASSIN, F., & BEGUIN, Y. (02 February 2014). Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide. European Journal of Haematology, 92 (2), 179-180. doi:10.1111/ejh.12233 Peer Reviewed verified by ORBi |
 | JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (2014). Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation. Belgian Journal of Hematology, 14. Peer Reviewed verified by ORBi |
 | JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2014). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial. Blood, 124, 33-41. doi:10.1182/blood-2014-01-546333 Peer Reviewed verified by ORBi |
 | HAFRAOUI, K., DE PRIJCK, B., & Beguin, Y. (2013). Leucémie myélomonocytaire chronique : diagnostic et thérapeutique. Revue Médicale Suisse, 9, 1512-1517. Peer Reviewed verified by ORBi |
 | BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552 Peer Reviewed verified by ORBi |
 | JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2013). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. Belgian Journal of Hematology, 16. Peer Reviewed verified by ORBi |
 | HAFRAOUI, K., CAERS, J., TASSIN, F., & Beguin, Y. (2013). Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide [Poster presentation]. BHS 28th General Annual Meeting, Gent, Belgium. |
 | Bonnet, C., CAERS, J., DE PRIJCK, B., HAFRAOUI, K., & Beguin, Y. (2011). Lymphome du manteau : prise en charge 2011. Revue Médicale Suisse, 7, 1644-1649. Peer Reviewed verified by ORBi |
 | Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011 Peer Reviewed verified by ORBi |
 | Hafraoui, K., Beguin, Y., & Baron, F. (2009). Cancers secondaires après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (10), 496-499. Peer reviewed |
 | Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation [Poster presentation]. 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium. |
 | Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning [Paper presentation]. 35th EBMT Annual Meeting. |
 | Hafraoui, K., Moutschen, M., Smet, J., Mascart, F., Schaaf-Lafontaine, N., & Fillet, G. (2009). Selective defect of anti-pneumococcal IgG in a patient with persistent polyclonal B cell lymphocytosis. European Journal of Internal Medicine, 20 (3), 62-5. doi:10.1016/j.ejim.2008.08.005 Peer Reviewed verified by ORBi |
 | Willems, E.* , Baron, F.* , Baudoux, E., Wanten, N., Seidel, L., Vanbellinghen, J.-F., Herens, C., Gothot, A., Frere, P., Bonnet, C., Hafraoui, K., Vanstraelen, G., Fillet, G., & Beguin, Y. (2009). Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia, 23 (3), 608-10. doi:10.1038/leu.2008.248 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2006). Nonmyeloablative stem cell transplantation with CD8-depleted or unmalipulated peripheral blood stem cells: a prospective randomized trial [Paper presentation]. 21st General Meeting of the Belgian Hematological Society. |
 | Vanstraelen, G., Baron, F., Willems, E., Bonnet, C., Hafraoui, K., Frere, P., Fillet, G., & Beguin, Y. (2006). Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response. Experimental Hematology, 34 (7), 841-50. doi:10.1016/j.exphem.2006.04.012 Peer reviewed |
 | Frere, P., Baron, F., Bonnet, C., Hafraoui, K., Pereira-Martins, M., Willems, E., Fillet, G., & Beguin, Y. (2006). Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplantation, 37 (4), 411-8. doi:10.1038/sj.bmt.1705255 Peer Reviewed verified by ORBi |
 | WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2005). Nonmyeloablative stem cell transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a prospective randomized trial. Blood, 106 (1075). Peer Reviewed verified by ORBi |
 | Vanstraelen, G., Baron, F., Frere, P., Hafraoui, K., Fillet, G., & Beguin, Y. (2005). Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica, 90 (9), 1269-70. Peer Reviewed verified by ORBi |
 | Hafraoui, K., Humblet-Baron, S., Baron, F., Beguin, Y., & Fillet, G. (2003). Comment je traite ... la leucemie myeloide chronique (LMC). Revue Médicale de Liège, 58 (1), 7-12. Peer reviewed |